• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

CuATSM

Background

In 2018, an Australian company called Collaborative Medicinal Development; LLC  released results from a Phase 1 clinical trial for a compound called CuATSM. Later trials (Phase 2 or 3) would be designed to further examine safety and to eventually determine if CuATSM had the ability to alter ALS/MND disease progression.

On January 7th, 2019, television spots and a media stated that CuATSM slowed disease progression in the Phase 1 clinical trial participants (Newswire press release). However, this Phase 1 trial was designed to only determine safety and dosing of CuATSM. These statements resulted in an international outcry for people living with ALS/MND to access CuATSM. Further studies, however, were required to provide a clear indication of whether these preliminary results were reliable.

Trial Design & Results

In late 2019, a Phase 2/3 clinical trial of 80 people started recruiting in Australia (NCT04082832). It was setup to provide stronger evidence for a treatment effect than the Phase 1 trial. The size of this Phase 2/3 trial meant however, that a very large slowing of disease progression would be required for a statistically significant effect to be seen.

The Phase 2/3 trial was completed in late 2021 however, the outcome of the trial has yet to be announced. It is very disappointing that Collaborative Medicinal Development, LLC decided not to release the results to this date.

In 2023, a peer reviewed article showed no alleviation of TDP-43 pathology or astrogliosis in 6 post-mortem brain samples from individuals affected by ALS and treated with CuATSM in clinical trials. This is in contrast with what had been observed in preclinical studies (Yang et al., 2023).

Summary

The SAC recommends that Alliance members refer to CuATSM as a drug that was recently studied for human safety in a small Phase 1 clinical trial by the company Collaborative Medicinal Development, LLC in Australia. It is the opinion of the SAC that, at  the doses tested, clinical grade CuATSM is considered safe. However, a press release also states that the company has seen a substantial slowing of disease progression. This Phase 1 clinical trial was not designed to make such a public statement and a number of aspects in its design require this result to be taken with as much caution as possible. Essentially, there is no substantiated scientific evidence that CuATSM has any advantageous effect on ALS/MND in humans.

To date, the follow-on trial results have not been published despite the trial completing in 2021. The SAC urges Collaborative Medicinal Development, LLC to report the outcomes of the trial as soon as possible to the community that has supported this trial. However, given that Collaborative Medicinal Development has been unresponsive to this request, the SAC has decided to move this note to the “drugs no longer in development” section of the Alliance website.

Please refer to the MND Association blog for a more detailed explanation.

International Alliance of ALS/MND Associations
April 2026


Disclaimer: The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • Barry de Reuver, Netherlands

    Barry de Reuver, Netherlands

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

  • Anderson Custodio Pinto, Brazil

    Anderson Custodio Pinto, Brazil

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Andrea Zicchieri, Italy

    Andrea Zicchieri, Italy
    AndreaZicchieri_conSLAncioItaly

  • Anthony Lynch, Australia

    Anthony Lynch, Australia

  • Inta Grubb, Australia

    Inta Grubb, Australia

  • Philip Brindle, England

    Philip Brindle, England

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Dr. Janmejay Pradhan, India

    Dr. Janmejay Pradhan, India

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Bayley, Australia

    Bayley, Australia

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Gisli Jonasson, Iceland

    Gisli Jonasson, Iceland

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Hans Dieter Olszewski, Germany

    Hans Dieter Olszewski, Germany

  • Ian Gale, Australia

    Ian Gale, Australia

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Liam Dwyer, England

    Liam Dwyer, England

  • Maurice LeClerc, Canada

    Maurice LeClerc, Canada

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Jean

    Jean
    jean

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Laurie Petit-Jean, France

    Laurie Petit-Jean, France

  • Angelique van der Lit-van Veldhuizen, Netherlands

    Angelique van der Lit-van Veldhuizen, Netherlands

  • Yolanda Armendariz, Mexico

    Yolanda Armendariz, Mexico

  • Kirsty Gerlach, New Zealand

    Kirsty Gerlach, New Zealand

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Jason Goodman, USA

    Jason Goodman, USA

  • John Russo, USA

    John Russo, USA
    final3878

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • Bob Spurrier, USA

    Bob Spurrier, USA

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Karl Hughes, Ireland

    Karl Hughes, Ireland

  • Ali Var, Turkey

    Ali Var, Turkey

  • Shera Mukherjee, India

    Shera Mukherjee, India

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login